The cardiac extracellular matrix (ECM) maintains the structural and mechanical integrity of the myocardium. We determined the alterations in the composition of the ECM coincident with the transition from compensated left ventricular hypertrophy (LVH) to symptomatic congestive heart failure (CHF) and the mechanisms underlying such changes. Heart failure was induced in ferrets by aortic banding. Myocardial collagen content was assessed by HPLC and histologically. Matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP) expression were evaluated using gelatin zymography and western blotting respectively. Left ventricular (LV) free wall thickness increased by 29% in asymptomatic LVH and was associated with a 20% increase in interstitial fibrosis (P<0.05). CHF was coincident with increased plasma angiotensin II levels (CHF, 149±48; LVH 40±19; sham, 5.6±1pg.ml The enhanced MMP-9 activity coincident with the transition to CHF provides potential therapeutic opportunities for managing the progression from asymptomatic LVH to symptomatic CHF.
Introduction
In the heart an intricate lattice of collagen containing extracellular matrix (ECM) surrounds both individual myocytes and myofibril bundles ensuring correct tissue geometry and aiding efficient vectoral transmission of force (4).
Whilst contractile dysfunction in heart failure has been attributed to alterations in cellular Ca 2+ homeostasis (8, 25) maladaptive remodelling of the cardiac ECM is also noted in various disease states (32, 36) and may contribute to systolic dysfunction through alterations in the tensile properties of the myocardium and in myocyte orientation (1) . To this end histological evidence for reduced interstitial collagen content and/or fragmented collagen distribution exists in diverse models of heart failure with cardiac dilatation (10, 33, 37, 38) .
Whereas collagen loss and fragmentation in heart failure have been observed in some studies, myocardial fibrosis has been noted in others, particularly where cardiac pathology is of an using Scion Image (www.scioncorp.com) and collagen content expressed as the percentage of nonzero (collagen-containing) pixels per tissue section.
The collagen content of the snap frozen myocardial samples was determined using pre-column derivatisation high performance liquid chromatography (HPLC) and fluorimetric detection of 9-fluorenylmehtyl chloroformate (FMOC) derivatised 4-hydroxyproline as previously described (34) .
3,4-dihydroproline (15Kg.ml -1 ) was added to each sample/standard as an internal control.
Fluorescent FMOC derivatives were separated using reverse phase HPLC using a 25cm*4.6mm
column packed with 5Km 300Å C-18 bonded silica and eluted with 50mmol.L -1 acetic acid and 35% acetonitrile. Fluorimetric quantification (N ex 260nm, N em 330nm) of 4-hydroxyproline was performed against a standard curve and samples normalised to the 3,4 dihydroproline peak to control for any loading differences. Collagen content was then calculated assuming that collagen contains 13.4% hydroxyproline (22).
Collagen cross-linking was determined from the ratio of pepsin insoluble to pepsin soluble collagen by adapting previously described methods (27, 28) . Approximately 50mg of frozen myocardium was lyophilised and subject to pepsin digestion in 0.5mol.L ): Tris, 50; CaCl 2 , 5 pH 7.8. Gels were stained in 0.25% coomassie blue, 50% methanol, 10% acetic acid for 5-10min and de-stained in 30% methanol and 1% acetic acid.
Substrate zymography was repeated three times for each sample and the density of gelatinolytic bands normalised to that obtained from an internal standard run in parallel on each gel. To confirm the presence of pro or active forms of MMPs, samples and HT1080 conditioned media serving as positive control were incubated with p-aminophenylmercuric acetate (APMA) as described (30) .
Tissue inhibitor of metalloproteinase protein levels and plasma angiotensin II concentrations
Myocardial samples were homogenised in RIPA buffer containing protease inhibitors, protein concentration determined and samples separated using denaturing SDS-PAGE on a 4-12% Bis-Tris gradient gel and transferred to PVDF membrane and blocked using 5% non-fat milk as previously described (8). TIMP-1, 2, 3 & 4 and TNF-immunodetection was performed using chemiluminescent substrate. Membranes were then stripped and re-probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Protein loading, sources and working concentrations of primary and secondary antibodies are summarised in Table 1. TIMP and TNF-protein expression was normalised to GAPDH protein expression and mean data from 3 repeats for each blot and 6-10 animals per experimental group are presented.
Plasma angiotensin II levels were assessed in a parallel study by ELISA (SPIbio, UK). Whole blood was collected in chilled EDTA tubes, plasma separated by centrigugation at 3000g and passed through phenyl cartridges (Amersham, UK) and angiotensin eluted with methanol.
Following evaporation of methanol under nitrogen, angiotensin samples and standards were resuspended in enzyme immunoassay buffer, Ellmans reagent added and quantified (absorbance spectrophotometry at 405nm).
Statistics: All data are expressed as mean±standard error of the mean for n animals. One or two way analysis of variance was used to compare experimental groups as appropriate and P<0.05 considered significant. Gelatin zymography revealed lytic bands at 64, 70 and 86kDa ( Figure 5A ). The 64 and 70kDa bands correspond to pro and active MMP-2 human gelatinase standards (data not shown). To establish that gelatinolytic activity is due to MMP activity samples were incubated with EDTA which abolished all activity ( Figure 5B ). To determine if the lytic activity at 86kDa was due to the pro or active form of MMP-9, samples and conditioned media from HT1080 cells were incubated with APMA ( Figure 5C ). APMA activation resulted in a shift in the size of the HT1080 conditioned media lytic bands from 92kDa (pro MMP-9) to 82kDa (active MMP-9) and the appearance of an additional band at 62kDa (active MMP-2). In tissue extracts there was no shift in the 86kDa band suggesting that active form of MMP-9 was present.
Results

Myocardial Dysfunction and Chamber Dilatation in
Figures 5D-F summarise gelatinolytic abundance in sham, LVH and CHF samples. There was no difference in pro MMP-2, active MMP-2 or total MMP-2 (data not shown) in all of the samples.
However, the amount of active MMP-9 was dramatically increased in the CHF group only, by 200% compared to the control and 175% compared to the LVH groups (P<0.01 vs. sham and LVH). However the mean relationships between myocardial collagen content and active MMP-9 abundance is best described using an exponential function (bottom panel, r 2 = 0.9, exopenent = 4.2).
Collagen cross-linking was determined from the ratio of pepsin insoluble:pesin soluble hydroxyproline. This ratio was unaltered by disease progression (sham 0.62±0.07, LVH 0.66±0.13
and CHF 0.69±0.09) thus suggesting that the loss of collagen from the myocardium with disease progression is key to the adverse geometric remodelling and onset of clinical symptoms observed.
Plasma angiotensin II concentrations were increased in CHF (CHF, 149±48; LVH 40±19; sham, 5.6±1pg.ml Figure 7A shows representative Western blots. These blots were then stripped and reprobed against GAPDH to control for loading differences (lower panel). Figure 7B summarises the TIMP:GAPDH protein ratios expressed relative to sham levels on each blot. Two-way analysis of variance (to analyse both between disease states and blots) failed to detect any difference in TIMP levels between sham, LVH and CHF at the time of sample collection i.e. sacrifice at the end of the experiments. Determination of myocardial TNF-expression also failed to detect any differences between the three experimental groups. The ratio between total MMP-2 abundance determined zymographically and TIMP expression is unaltered ( Figure 7C ) whereas that between MMP-9 abundance and TIMP's 1, 2 and 4 is increased only in the CHF group (P<0.05).
Discussion
Remodelling of the ECM is believed to influence myocardial structure and function in health and disease. To our knowledge this is the first report directly examining the alterations in the relationships between myocardial collagen content, collagen distribution, cardiac function and MMP activity during the transition from compensated asymptomatic LVH to decompensated symptomatic CHF. The principal observation is that of considerable disruption to collagen distribution within the cardiac ECM and a loss of collagen coincident with chamber dilatation and onset of clinical symptoms. We propose that the loss of collagen from the myocardial interstitium occurs as a consequence of an increase in MMP-9 activity.
Reduced cardiac collagen content and altered distribution with progression to symptomatic congestive heart failure: Hydroxyproline quantification and histological analysis were used to quantify myocardial collagen content in this study. Both methods yielded quantitatively similar collagen contents. In agreement with other models of heart failure and clinical observations (10, 29, 33, 39) collagen content was reduced at CHF coincident with disrupted distribution evident histologically. In the asymptomatic LVH group a moderate interstitial fibrosis was observed histologically when the endocardial, epicardial and vascular regions were excluded from analysis.
This is consistent with a number of other studies and the accepted dogma of myocardial fibrosis in cardiac disease states (15, 16, 24, 26, 41). Nevertheless, the hydroxyproline quantification demonstrated a reduction in total myocardial collagen content in the asymptomatic LVH group that likely reflects differential remodelling of collagen within the interstitial, vascular and surface layers of the heart at this time point.
We propose that the loss of collagen from the interstitium is a critical step in the development of cardiac dilatation and onset of clinical symptoms of heart failure. In agreement with this assertion, data from a recent study by Heymans et al (15) demonstrated an increased myocardial collagen content two weeks after thoracic aortic banding in mice that then decreased seven weeks after banding when cardiac dilatation and reduced ejection fraction were observed. Additionally, both
Fedak et al (10) using the cardiomyopathic hamster and Spinale et al (33) in tachypacing heart failure in the pig reported that the collagen weave was markedly reduced and disrupted. Weber et al (37) noted similar loss of collagen and altered distribution of collagen in explanted failing human hearts suggesting that in end stage heart failure a commonality of mechanism exists between diverse species and disease models. The apparent discrepancy between the present study and those of human hypertension (16, 26) or animal models of pressure overload cardiac dysfunction (24) where interstitial fibrosis is considered the norm, may simply reflect the end stage nature of the disease process.
Differential changes in MMP and TIMP expression in CHF,:
In the present study gelatin 14, 39). In the present study no changes in myocardial TNF-were observed at the time of sample collection. However, involvement of other cytokines, in mediating increased MMP-9 abundance cannot be excluded. A potential mechanism by which MMP-9, rather than MMP-2, is selectively up-regulated in this study (and e.g. (12, 23)) may reside in the unique NF -B transcription binding site in the promoter region of MMP-9 (for review see (7)). The NF-B pathway is known to be activated by angiotensin II and increases MMP-9 transcription (31) which, together with the increased in collagen type 1 synthesis in cardiac fibroblasts by the same pathway (5), may underlie much of the beneficial effects of angiotensin converting enzyme inhibitors in the management of cardiac disease states (19). Further evidence in support of the role played by MMP-9 in the deleterious remodelling processes of heart disease is provided by the targeted deletion of MMP-9 whereby cardiac remodelling was substantially attenuated both post infarction (9) and following aortic banding (15) in mice. Furthermore, the use of less specific pharmacological interventions that target MMP-9 activity also result in improved cardiac function and limit structural remodelling (18, 40).
In the present study neither myocardial TIMP protein levels nor collagen cross-linking were found to be altered at the times of sacrifice. Since this study is not designed longitudinally due to the impracticality of obtaining serial samples from the same heart we cannot completely rule out the possibility that changes in TIMP expression, activation of other MMP's or changes in collagen cross-linking occur at intermediate stages of disease progression. However, the increase in MMP-9 observed in this study at the time of chamber dilatation, reduced fractional shortening and onset of clinical symptoms of heart failure is indicative of the role of MMP-9 in the deleterious progression from compensated LVH to symptomatic CHF.
Study limitations:
Since we are unable to obtain serial samples from the same heart an important consideration is whether the symptomatic CHF group undergo a different disease process to the LVH group that remain asymptomatic for considerably longer. To address this, we have performed echocardiography at an intermediate time point in animals that later developed CHF and have found similar changes in FWT (5.0±0.3mm at LVH vs. 3.1±0.1mm at CHF) and LVEDD (20.5±0.1mm at LVH vs. 23.1±0.3mm at CHF) suggesting that indeed those animals that later become symptomatic do indeed experience an asymptomatic hypertrophic phase of cardiac disease in the first instance.
We believe that in the present study the reason why some animals remain in a compensated LVH phase arises because the degree of aortic compression, and therefore overload placed on the left ventricle, is subtly different between animals due to the extent of swelling of the ameroid material in the occluder placed around the ascending aorta.
MMPs are tightly regulated by a family of tissue inhibitors (TIMP's) (32) . Whilst our data suggests that the expression level of TIMP's is unaltered we can not address the stoichiometric relationship between TIMP's and MMPs. Additionally, zymograms do not evaluate potential contributions to the overall collagenolytic activity of the heart by other serine and cysteine proteases. Nevertheless, two important points support our suggestion that MMP-9 is critical to the remodelling process observed in the present study; i) there was no shift in the total MMP-2 levels or the ratio of pro to active MMP-2 and ii) only active MMP-9 was observed .
In conclusion, it is becoming clear that the myocardial matrix is a dynamic structure whose continuous turnover is under fine control. Furthermore, a maladaptive response to injury or increased workload, resulting in adverse myocardial extracellular matrix abundance and distribution can contribute to LV dilation and heart failure. We conclude an increased MMP-9 activity, resulting in a loss of the collagenous interstitium may play a causative role in the deterioration of contractile function, LV dilatation and the progression to heart failure and may provide a novel pharmacological target to prevent the progression from compensated asymptomatic LVH to symptomatic CHF. 
